## **CLAIMS**

We claim:

1. A compound having the following structure:

or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof,

wherein:

A is  $-(CR_{3a}R_{3b})_nNR_1R_2$  or  $R_5$ ;

Y is  $-(CR_{3a}R_{3b})_nNR_1R_2$ ,  $R_4$ , or  $R_5$ ;

with the proviso that one of A or Y, but not both, is  $-(CR_{3a}R_{3b})_nNR_1R_2$ ;

B is  $R_4$  or  $-X-R_5$ ;

X is O, S or a bond;

n is 2, 3 or 4;

 $R_1$  and  $R_2$  are the same or different and independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(R_8)(=NR_9)$  or  $-C(NR_6R_7)(=NR_9)$ ;

or  $R_1$  and  $R_2$  taken together with the nitrogen atom to which they are attached form a heterocycle or a substituted heterocycle;

 $R_{3a}$  and  $R_{3b}$  are the same or different and, at each occurrence, independently hydrogen, alkyl, substituted alkyl, alkoxy, alkylthio, alkylamino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -COOR<sub>10</sub> or -CONR<sub>6</sub>R<sub>7</sub>;

or  $R_{3a}$  and  $R_{3b}$  taken together with the carbon atom to which they are attached form a homocycle, substituted homocycle, heterocycle or substituted heterocycle;

or  $R_{3a}$  and the carbon to which it is attached taken together with  $R_1$  and the nitrogen to which it is attached form a heterocycle or substituted heterocycle;

R<sub>4</sub> is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl; R<sub>5</sub> is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

R<sub>6</sub> and R<sub>7</sub> are the same or different independently hydrogen, alkyl, substituted alkyl, aryl, substituted arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

R<sub>8</sub> is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

R<sub>9</sub> is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

and

R<sub>10</sub> is hydrogen, alkyl, or substituted alkyl.

- 2. The compound of claim 1 wherein A is  $-(CR_{3a}R_{3b})_nNR_1R_2$ .
- 3. The compound of claim 1 wherein Y is  $-(CR_{3a}R_{3b})_nNR_1R$ .
- 4. The compound of claim 1 wherein B is  $-X-R_5$ .
- 5. The compound of claim 4 wherein X is a direct bond.
- 6. The compound of claim 4 where X is -O or -S-.
- 7. The compound of claim 1 wherein R<sub>1</sub> is hydrogen, alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, heterocyclealkyl or substituted heterocyclealkyl.

- 8. The compound of claim 1 wherein R<sub>4</sub> is substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroarylalkyl or substituted heteroarylalkyl.
- 9. The compound of claim 1 wherein  $R_5$  is substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroarylalkyl or substituted heteroarylalkyl.
- 10. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 11. A method for antagonizing gonadotropin-releasing hormone in a subject in need thereof, comprising administering to the subject an effective amount of a compound of claim 1.
- 12. A method for treating a sex-hormone related condition of a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 10.
- 13. The method of claim 12 wherein the sex-hormone related condition is cancer, benign prostatic hypertrophy or myoma of the uterus.
- 14. The method of claim 13 wherein the cancer is prostatic cancer, uterine cancer, breast cancer or pituitary gonadotroph adenomas.
- 15. The method of claim 12 wherein the sex-hormone related condition is endometriosis, polycystic ovarian disease, uterine fibroids or precocious puberty.

- 16. A method for preventing pregnancy of a subject in need thereof, comprising administering an effective amount of the pharmaceutical composition of claim 10.
- 17. A method for treating lupus erythematosis, irritable bowel syndrome, premenstrual syndrome, hirsutism, short stature or sleep disorders of a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 10.